MARC details
| 000 -LEADER |
|---|
| fixed length control field |
10283nmm a22004698i 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20230705152722.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
180619s2018 nju ob 000 0 eng |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
|---|
| LC control number |
2018029535 |
| 066 ## - CHARACTER SETS PRESENT |
|---|
| Alternate G0 or G1 character set |
(S |
| 015 ## - NATIONAL BIBLIOGRAPHY NUMBER |
|---|
| National bibliography number |
GBB8D4524 |
| Source |
bnb |
| 016 7# - NATIONAL BIBLIOGRAPHIC AGENCY CONTROL NUMBER |
|---|
| Record control number |
018980288 |
| Source |
Uk |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781119460459 |
| Qualifying information |
(electronic bk.) |
|
|---|
| International Standard Book Number |
111946045X |
| Qualifying information |
(electronic bk.) |
|
|---|
| International Standard Book Number |
9781119460435 |
| Qualifying information |
(electronic bk. : oBook) |
|
|---|
| International Standard Book Number |
1119460433 |
| Qualifying information |
(electronic bk. : oBook) |
|
|---|
| Canceled/invalid ISBN |
9781119460459 |
|
|---|
| Canceled/invalid ISBN |
111946045X |
|
|---|
| Canceled/invalid ISBN |
9781119460442 |
|
|---|
| Canceled/invalid ISBN |
1119460441 |
|
|---|
| Canceled/invalid ISBN |
9781119460107 (hardback) |
| 037 ## - SOURCE OF ACQUISITION |
|---|
| Stock number |
9781119460459 |
| Source of stock number/acquisition |
Wiley |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MED |
| Subject category code subdivision |
071000 |
| Source |
bisacsh |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.1/9 |
| Edition number |
23 |
| 084 ## - OTHER CLASSIFICATION NUMBER |
|---|
| Classification number |
TEC021000 |
| Number source |
bisacsh |
| 100 ## - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Sharon, Madhuri, |
| Relator term |
author. |
| 9 (RLIN) |
22046 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Carbon dots as theranostic agents / |
| Statement of responsibility, etc. |
Madhuri Sharon and Ashmi Mewada. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Hoboken, New Jersey : |
| Name of publisher, distributor, etc. |
Wiley-Scrivener, |
| Date of publication, distribution, etc. |
[2018] |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
1 online resource. |
| 490 1# - SERIES STATEMENT |
|---|
| Series statement |
Advances in nanotechnology & applications |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
"Sales handles: - Biocompatible Carbon Dots as a suitable nanoparticle for health care Swarming Carbon dots can cross Blood Brain Barrier and deliver drugs for Neurodegenerative disease Conjugated/functionalized Carbon dots as tri-functional nano-worms for anti-cancer drug delivery, photothermal therapy and bioimaging Also discusses the suitability of Carbon Dots as payload for plant nutrient and drugs Market description: Scientists, researchers, clinicians, and biotechnologists working on theranostics; biomedical industrial sectors working on system biology, diagnostics, imaging, image-guided therapy employing state-of-the-art techniques; and PhD, master and under graduate level courses on therapeutics, biosensors, and translational medicine and personalized medicine"-- |
| Assigning source |
Provided by publisher. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Includes bibliographical references. |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Nanoparticles. |
| 9 (RLIN) |
22047 |
|
|---|
| Topical term or geographic name entry element |
Nanostructured materials. |
| 9 (RLIN) |
22048 |
|
|---|
| Topical term or geographic name entry element |
Carbon. |
| 9 (RLIN) |
22049 |
|
|---|
| Topical term or geographic name entry element |
TECHNOLOGY & ENGINEERING / Material Science. |
| Source of heading or term |
bisacsh |
| 9 (RLIN) |
22050 |
|
|---|
| Topical term or geographic name entry element |
Carbon. |
| Source of heading or term |
fast |
| Authority record control number or standard number |
(OCoLC)fst00846775 |
| 9 (RLIN) |
22049 |
|
|---|
| Topical term or geographic name entry element |
Nanoparticles. |
| Source of heading or term |
fast |
| Authority record control number or standard number |
(OCoLC)fst01032624 |
| 9 (RLIN) |
22047 |
|
|---|
| Topical term or geographic name entry element |
Nanostructured materials. |
| Source of heading or term |
fast |
| Authority record control number or standard number |
(OCoLC)fst01032630 |
| 9 (RLIN) |
22048 |
|
|---|
| Topical term or geographic name entry element |
MEDICAL / Pharmacology. |
| Source of heading or term |
bisacsh |
| 9 (RLIN) |
22051 |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="https://doi.org/10.1002/9781119460435">https://doi.org/10.1002/9781119460435</a> |
| Public note |
Wiley Online Library |
| 880 0# - ALTERNATE GRAPHIC REPRESENTATION |
|---|
| Linkage |
505-00/(S |
| a |
<p>Preface</p> <p><b>1. Carbon Dots: Discovery, Synthesis and Characterization 1</b></p> <p>1.1. Background 1</p> <p>1.2. Introduction to QD 2</p> <p>1.2.1. What is Quantum Mechanics4</p> <p>1.2.2. Quantum Confinement 7</p> <p>1.2.3. Discovery and History of Carbon Dots 8</p> <p>1.3. Carbon QD and Graphene QD 9</p> <p>1.4. Various Methods of Synthesis of Carbon Dots 10</p> <p>1.4.1. Electrochemical Methods 11</p> <p>1.4.2. Combustion and Thermal Oxidation Method 13</p> <p>1.4.3. Hydrothermal Oxidation Method 15</p> <p>1.4.4. Solvothermal Method 18</p> <p>1.4.5. Laser Ablation of Graphite 18</p> <p>1.4.6. Pulsed Laser Irradiation of Carbon Source 20</p> <p>1.4.7. Arc Discharge Method 20</p> <p>1.4.8. Plasma Treatment 21</p> <p>1.4.9. Opening of Fullerene Cage 22</p> <p>1.4.10. Ultrasonication Method 22</p> <p>1.4.11. Microwave-Assisted Method 23</p> <p>1.4.12. Chemical Methods 26</p> <p>1.4.13. Supported Synthetic Procedure 26</p> <p>1.4.14. Biogenic Method 28</p> <p>1.5. Characterization of Carbon Dots 31</p> <p>1.5.1. Microscopic Methods 32</p> <p>1.5.1.1. SEM and TEM Characterization 32</p> <p>1.5.1.2. AFM and STM Characterization 34</p> <p>1.5.2. Spectroscopic Methods 35</p> <p>1.5.2.1. UV-Vis Spectroscopy and its Application for Band Gap Determination 37</p> <p>1.5.2.2. Fluorescence Spectrometry 37</p> <p>1.5.2.3. Fourier Transform Infrared (FTIR) Spectroscopy 38</p> <p>1.5.2.4. X-Ray Diffraction (XRD) Analysis 40</p> <p>1.5.2.5. X-Ray Photoelectron Spectroscopy (XPS) 41</p> <p>1.5.2.6. Dynamic Light Scattering/Photon Correlation Spectroscopy (DLS/PCS) 41</p> <p>1.5.2.7. Dual Polarization Interferometry (DPI) 42</p> <p>1.5.2.8. Raman Spectroscopy 43</p> <p>1.5.2.9. Nuclear Magnetic Resonance (NMR) Spectroscopy 44</p> <p>1.6. Summary 45</p> <p><b>2. Properties of Carbon Dots 47</b></p> <p>2.1. Introduction 47</p> <p>2.2. Optical Properties 49</p> <p>2.2.1. Absorbance 51</p> <p>2.2.2. Photo-Induced Electron Transfer (PET) with CDs 52</p> <p>2.2.3. Fluorescence/Photoluminescence (PL) 53</p> <p>2.2.3.1. Multiphoton Excitation 60</p> <p>2.2.3.2. Upconversion Photoluminescence 61</p> <p>2.2.3.3. Lack of Blinking 63</p> <p>2.2.3.4. Resistance to Photobleaching 64</p> <p>2.2.4. Photocatalytic Property 65</p> <p>2.3. Chemically Inert 67</p> <p>2.4. Easy Functionalization 67</p> <p>2.5. Water Solubility 68</p> <p>2.6. Low Toxicity 68</p> <p>2.7. Biocompatibility 69</p> <p>2.8. Summary 70</p> <p><b>3. Carbon Dots and Conjugates 71</b></p> <p>3.1. Introduction 71</p> <p>3.2. Why Conjugation of Carbon Dots74</p> <p>3.3. Types of Carbon Dot Conjugates and Their Applications 76</p> <p>3.3.1. Biogenic Compounds Conjugated with Carbon Dots 77</p> <p>3.3.1.1. CDs Conjugated with Proteins/Peptides 78</p> <p>3.3.1.2. CD Conjugates of Amino: Carboxylic Acid Ratio 80</p> <p>3.3.1.3. CDs Conjugated with DNA 80</p> <p>3.3.1.4. CDs Conjugated with RNase and SiRNA 84</p> <p>3.3.1.5. CDs Conjugated with Lipid 86</p> <p>3.3.1.6. CDs Conjugated with Folic Acid 86</p> <p>3.3.1.7. CDs Conjugated with Chitosan 88</p> <p>3.3.1.8. CDs Conjugated with Digitonin 89</p> <p>3.3.2. Inorganic Heteroatoms Conjugated with CDs 90</p> <p>3.3.2.1. CDs Conjugated with Gold Nanoparticles 91</p> <p>3.3.2.2. CDs Conjugated with Silica 92</p> <p>3.3.2.3. CDs Conjugated with ZnO 94</p> <p>3.3.2.4. CDs Conjugated with CdS 95</p> <p>3.3.2.5. CDs Conjugated with Strontium Oxide 96</p> <p>3.3.2.6. CDs Conjugated with Gadolinium(III) 97</p> <p>3.3.2.7. CDs Conjugated with Europium 97</p> <p>3.3.2.8. CDs Conjugated/Doped with Nitrogen, Sulphur, Phosphorus and Boron 99</p> <p>3.3.3. Carbon Dots Conjugated with Organic Material 100</p> <p>3.3.3.1. PEG (Polyethylene Glycol) 101</p> <p>3.3.3.2. CDs Conjugated with PEI (Polyethylenimin) or Polyaziridine 102</p> <p>3.3.3.3. CDs Conjugated with α-Cyclodextrin 105</p> <p>3.3.3.4. CDs Conjugated with Cysteamine 106</p> <p>3.3.3.5. CDs Conjugated with Dihydrolipoic Acid 106</p> <p>3.3.3.6. CDs Conjugated with Polyamidoamine (PAMAM) Dendrimers 107</p> <p>3.3.3.7. CDs Covalently Conjugated with Rhodamine B Dyes 108</p> <p>3.3.3.8. CDs Conjugated with Fe-Aminoclay (FeAC) 109</p> <p>3.3.3.9. CDs Conjugated with MWCNT 109</p> <p>3.3.4. CDs Conjugated with Antibiotics 110</p> <p>3.3.4.1. CDs Conjugated with Ciprofloxacin 111</p> <p>3.3.4.2. CDs Conjugated with Tetracycline 114</p> <p>3.3.4.3. CDs Conjugated with Vancomycin 114</p> <p>3.3.4.4. CDs Conjugated with Ampicillin 115</p> <p>3.3.4.5. CDs Conjugated with Streptomycin 116</p> <p>3.3.5. CDs Conjugated with Anti-Neurodegenerative Drugs for Delivery to Central Nervous System 118</p> <p>3.3.5.1. CDs Conjugated with Haloperidol 119</p> <p>3.3.5.2. CDs Conjugated with Transferrin 124</p> <p>3.3.5.3. CDs Conjugated with Curcumin 125</p> <p>3.3.6. CDs Conjugated with Anticancer Drugs 128</p> <p>3.3.6.1. CDs Conjugated with Doxorubicin 128</p> <p>3.3.6.2. CDs Conjugated with Cisplatin 130</p> <p>3.4. Summary 132</p> <p><b>4. CD as Drug Delivery Vehicle 133</b></p> <p>4.1. Introduction 133</p> <p>4.2. Considerations in Using CD as Drug Delivery Vehicle 136</p> <p>4.3. Designs of CD-Based Drug Delivery System 137</p> <p>4.3.1. Designing for Water-Insoluble Drugs 138</p> <p>4.3.2. Designing for Targeting Tumor Location 138</p> <p>4.3.3. Designing a Theranostic Nanomedicine 139</p> <p>4.3.4. Designing a Photoresponsive Nzzano Drug Delivery System 139</p> <p>4.3.5. Designing for Gene Delivery 140</p> <p>4.3.6. Designing for Antibiotics Delivery 141</p> <p>4.4. Carbon Dots for Delivery of Anti-Cancer Drug 142</p> <p>4.4.1. A Brief Introduction to Cancer 143</p> <p>4.4.2. Necessity of Drug Targeting in Cancer Therapy 144</p> <p>4.4.3. Targeting Angiogenesis with CD 144</p> <p>4.4.4. Various CD Conjugates for Delivering Anti-Cancer Drug 145</p> <p>4.4.5. CD for pH-Dependent Drug Release 146</p> <p>4.4.6. CD for Drug Delivery to Renal Cancer 147</p> <p>4.4.7. CD for Drug Delivery to Lung Cancer 148</p> <p>4.4.8. CD for Drug Delivery to Breast Cancer 149</p> <p>4.5. CD for Drug Delivery to Neurodegenerative Disease 150</p> <p>4.6. CD for Gene Therapy 151</p> <p>4.7. CD to Monitor Delivery of SiRNA 152</p> <p>4.8. Challenges in Using CD as Drug Delivery Vehicle 152</p> <p>4.8.1. Prevention of Drug from Biological Degradation 153</p> <p>4.8.2. Effective Targeting 154</p> <p>4.8.3. Patient Compliance 155</p> <p>4.8.4. Cost Effectiveness 155</p> <p>4.9. Suitability of CD-Conjugated Drugs 156</p> <p>4.9.1. For Oral Drug Delivery 156</p> <p>4.9.2. By Inhalation 156</p> <p>4.9.3. As Transdermal Drug Delivery 157</p> <p>4.9.4. As Injection 157</p> <p>4.10. Summary 157</p> <p><b>5</b><b>. </b><b>Carbon Dots for Cell Imaging and Diagnostics 159</b></p> <p>5.1. Introduction 159</p> <p>5.2. Bioimaging 162</p> <p>5.2.1. Bioimaging of Cancerous Cells 166</p> <p>5.2.1.1. HeLa Cells 168</p> <p>5.2.1.2<b>. </b>Human Breast Cancer MCF-7 Cells and Human Breast Tumor Cells MDA-MB-468 170</p> <p>5.2.1.3<b>. </b>B16F11 and HEK293 Cells 171</p> <p>5.2.1.4<b>. </b>Ehrlich Ascites Carcinoma (EAC) Cells 173</p> <p>5.2.1.5<b>. </b>Human U87 Cell 173</p> <p>5.2.1.6<b>. </b>MGC-803 Human Gastric Cancer Cells 174</p> <p>5.2.1.7<b>. </b>A549 Adenocarcinomic Human Alveolar (Lung) Basal Epithelial Cells 175</p> <p>5.2.1.8<b>. </b>Human Hepatocellular Carcinoma Cells 175</p> <p>5.2.1.9<b>. </b>Kidney Proximal Tubule Cell Line(LLC-PK1) 176</p> <p>5.2.1.10<b>. </b>C6 Glioma Cells 177</p> <p>5.2.2<b>. </b>Bioimaging of Nucleus 178</p> <p>5.2.3<b>. </b>Bioimaging of Virus 180</p> <p>5.2.4<b>. </b>Bioimaging of Bacteria 181</p> <p>5.2.5<b>. </b>Bioimaging of Drosophila melanogaster 183</p> <p>5.3<b>. </b>CDs as Sensor 184</p> <p>5.3.1<b>. </b>Intracellular Detection of Ions 185</p> <p>5.3.1.1<b>. </b>Detection of Ag Ions 185</p> <p>5.3.1.2<b>. </b>CD for Detection of Cu Ion 187</p> <p>5.3.1.3< |
